FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person – Dinarello Charles A				2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)														
(Last) (First) (Middle) 333 15TH STREET				3. Date of Earliest Transaction (Month/Day/Year) 02/13/2018 X Director Officer (give title below) Other (specify below)														
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person														
BOULDI (Cit	ER, CO 80:	(State)	(Zip)			7	Tabla I	Non De	. wixe	etivo (Cogneitic	s A aqui						
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if		te, if	3. Tra Code (Instr.	. 8)	4. Section (A) or (Instr.		ities Acq isposed (4 and 5) (A) or (D)	uired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		lowing	6. Ownership Form:	Beneficia Ownersh		
Common Stock			02/13/2018				N.		+	000			13,212				D	
Common Stock		02/13/2018				S		2,4	195		§ 135.76	10,717				D		
Common Stock			02/13/2018				S		2,5	505		36.36 2)	8,212				D	
Reminder:	Report on a	separate line for ea	ach class of securitie	es benefic	ially (owne	ed direc	Pers	son: tain	s who	this fo	rm are ı	not requ	ired	of inform to respond	nd unless t		1474 (9-0
			Table II -	Derivativ									Owned					
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, i	4. Transaction Code ar) (Instr. 8)		5. Number of		6. Date Exercisab Expiration Date (Month/Day/Year		le and	7. Title Amour Underl Securit	Title and nount of iderlying curities str. 3 and 4)		Derivative Security (Instr. 5)		Owners Form o Derivat Securit Direct (or Indir	ive Owne y: (Instr. D) ect	
				Code	V	(A)	(D)	Date Exercisa	ıble	Exp Dat	oiration e	Title	Amo or Nun of Shar	nber				
Stock Option (right to buy)	\$ 125.05							<u>(3</u>)	10/	26/2027	7 Comm	non ck 3,1	25		3,125	D	
Stock Option (right to buy)	\$ 101.19							10/26/2	2017	7 10/	26/2026	6 Comn Stoc	4 4	85		3,985	D	
Stock Option (right to buy)	\$ 87.34							10/29/2	2016	5 10/	28/2025	Stoc	14/	60		4,260	D	
Stock Option (right to buy)	\$ 91.78							10/30/2	2014	10/	30/2024	4 Comm Stoc		000		4,000	D	
Stock Option (right to buy)	\$ 87.39							10/31/2	2013	3 10/	30/2023	3 Comm Stoc	4.0	000		4,000	D	
Stock Option (right to buy)	\$ 66.9							10/25/2	2012	2 10/	24/2022	2 Comm Stoc		000		5,000	D	
Stock																		

Option (right to buy)	\$ 70.35					10/27/2011	10/26/2021	Common Stock	5,000		5,000	D	
huy) Stock Option (right to buy)	\$ 61.46					10/28/2010	10/27/2020	Common Stock	5,000		5,000	D	
Stock Option (right to buy)	\$ 63.03					10/29/2009	10/28/2019	Common Stock	5,000		5,000	D	
Stock Option (right to buy)	\$ 65.47	02/13/2018	M	5,0	000	10/23/2008	10/22/2018	Common Stock	5,000	\$ 0	0	D	

Reporting Owners

D	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Dinarello Charles A									
333 15TH STREET	X								
BOULDER, CO 80302									

Signatures

/s/ Sarah Tucher as Attorney-in-Fact for Charles A. Dinarello pursuant to Power of Attorney previously filed.	02/15/2018
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$135.61 to \$135.875, inclusive. The reporting (1) person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$136.03 to \$136.66, inclusive. The reporting (2) person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (3) The option vests on the earlier of the one year anniversary of the grant date (10/26/17) or the date of Bio-Techne's 2018 annual meeting of shareholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.